UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027901
Receipt number R000031968
Scientific Title Examination on an influence of a test food product on knee joint pain
Date of disclosure of the study information 2017/06/26
Last modified on 2018/02/01 10:26:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination on an influence of a test food product on knee joint pain

Acronym

Examination on an influence of a test food product on knee joint pain

Scientific Title

Examination on an influence of a test food product on knee joint pain

Scientific Title:Acronym

Examination on an influence of a test food product on knee joint pain

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Orthopedics Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine an influence of a test food product on knee joint pain by selecting males and females of Japanese nationality aged 40 and over, below 75 who are aware of knee pain but have not received orthopedic treatment as subjects and assigning them to take the test food product on a continuous basis.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

JKOM survey

Key secondary outcomes

VAS survey


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

6-week intake of the test food

Interventions/Control_2

6-week intake of the placebo food

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1.Subjects giving written informed consent
2.To examine an influence of a test food product on knee joint pain by selecting males and females of Japanese nationality aged 40 and over, below 75 who are aware of knee pain but have not received orthopedic treatm

Key exclusion criteria

1.Currently seeing a doctor for treatment of knee joint pain
2.Currently in treatment with medication
3.Presence or previous history of allergy to medication and/or food (especially, shrimps and crabs)
4.Presence or previous history of a severe disorder(s) such as diabetes, a circulatory disease, a hepatic disease, a renal disease, or a cardiac disease
5.Currently in treatment of rheumatism
6.Previous history of knee surgery
7.Plan to undergo medical treatment on knees during the study
8.Underwent an intraarticular injection of hyaluronic acid within two weeks before the selection or intraarticular injection of steroids within three months before the selection
9.Diagnosed with a bone or joint-related diseases such as a bone fracture or a sprain within the past three months
10.Regular intake of a health food product that contains hyaluronic acid, glucosamine, chondroitin sulfate, quercetin glycoside, vitamin D, or amino-acid formulation, and the intention of consuming the product during the study
11.Regular intake of medication with an influence on the evaluation of this study (particularly, a pharmaceutical product that contains glucosamine, chondroitin sulfate, vitamin D, or amino-acid formulation, or a pharmaceutical product for treatment of osteoporosis)
12.Regular use of an assistive cane
13.Regular intake of warfarin (product names: Warfarin, Warin, Arefarin, Warfarin, etc.) for treatment of cerebral infarction, a cardiac disease, or the like
14.Nursing or pregnant, or desired to become pregnant during the study
15.Presence or previous history of psychiatric visits for depression, a sleep disorder, etc.
16.Determined by the investigator to be unsuitable for enrollment in this study

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ochitani Daisuke

Organization

Clinical Development Division

Division name

Clinical Development Division

Zip code


Address

Oekkusu Bldg10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

81-3-3431-1260

Email

ochitani@huma-c.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ochitani Daisuke

Organization

HUMA R&D CORP

Division name

Clinical Development Division

Zip code


Address

Oekkusu Bldg10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

81-3-3431-1260

Homepage URL


Email

ochitani@huma-c.co.jp


Sponsor or person

Institute

HUMA R&D CORP

Institute

Department

Personal name



Funding Source

Organization

MYCARE Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 06 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 05 Month 12 Day

Date of IRB


Anticipated trial start date

2017 Year 06 Month 12 Day

Last follow-up date

2017 Year 08 Month 07 Day

Date of closure to data entry

2017 Year 08 Month 25 Day

Date trial data considered complete

2017 Year 08 Month 25 Day

Date analysis concluded

2017 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2017 Year 06 Month 23 Day

Last modified on

2018 Year 02 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031968


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name